Immunis.AI closes on funding for immunogenomic platform

LabPulse.com staff writers
Sep 30, 2021
2019 08 05 19 10 8249 Dollar Sign 400

Immunis.AI recently closed on additional financing that brings its total raised to $40 million to date for the ongoing development of its immunogenomic platform.

The company said the funding will support further validation and commercialization of the company's prostate cancer molecular test and will expand development of new tests in breast, colon, lung cancer, and other cancers.

Latest in Lung Cancer
Lung Cancer Hotspot Social
U.K. researchers get funding for lung cancer vaccine development
April 4, 2024
Lung Cancer Hotspot Social
Roche data release raises hopes TIGIT drugs can improve lung cancer survival
August 25, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Lung Cancer2 Social
Biodesix touts cost-saving potential of pulmonary nodule tests
May 30, 2023
Related Stories
2021 02 13 00 35 3916 Prostate Cancer 400
Prostate Cancer
Immunis.AI touts results from prostate liquid biopsy study
2019 09 09 20 46 2283 Lung Cancer 400
Lung Cancer
Researchers tout success of AI blood testing tech
2019 09 09 20 46 2283 Lung Cancer 400
Lung Cancer
Liquid biopsy may detect ALK fusions in lung cancer patients
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Lung Cancer
U.K. researchers get funding for lung cancer vaccine development
By Matt Limb
Researchers are working to develop a lung cancer vaccine in the U.K. with 1.7 million pounds ($2.2 million) funding from leading charities.
April 4, 2024
Lung Cancer Hotspot Social
Roche data release raises hopes TIGIT drugs can improve lung cancer survival
By Nick Paul Taylor
Roche's inadvertent release of interim data from its ongoing late-phase clinical trial has raised hopes that its anti-TIGIT immunotherapy may improve the survival rate of lung cancer patients.
August 25, 2023
Lung Cancer Hotspot Social
Machine learning models, blood biomarkers in research predict future disease risk
By Nick Paul Taylor
Researchers found that analyzing genomic information and blood biomarkers is more accurate and cost-effective than analyzing genomic data alone.
June 12, 2023
Artificial Intelligence Ai Suit Social
Biodesix touts cost-saving potential of pulmonary nodule tests
By LabPulse.com staff writers
Its analyses estimated cost savings in a hypothetical population of one million patients in a U.S. Medicare or commercial payer setting over a two-year timeline.
May 30, 2023
Lung Cancer2 Social
Biomarker predicts response to chemo-immunotherapy in lung cancer patients
By Nick Paul Taylor
Researchers see a correlation between CX3CR1 expression and outcomes in NSCLC patients treated with chemo-immunotherapy.
May 15, 2023
Lung Cancer2 Social
Thermo Fisher Scientific, Pfizer collaborate to broaden NGS testing in underserved countries
By LabPulse.com staff writers
Under the agreement, Thermo Fisher will select local labs for its NGS technology, ensuring they have the infrastructure, trained staff, and quality control measures to meet industry standards to conduct NGS testing for breast and lung cancer.
May 9, 2023
Sequencing Dna Rna Social
Oncocyte prices $13.86M public offering to support test development, commercialization
By LabPulse.com staff writers
Oncocyte intends to use the net proceeds from the offering primarily to promote the development and commercialization of VitaGraft, DetermaIO, and DetermaCNI precision diagnostic tests.
April 3, 2023
Lung Cancer2 Social
Micronoma receives FDA breakthrough device designation for liquid biopsy assay to detect lung carcinoma
By LabPulse.com staff writers
The company noted that as a result of the designation, it can expect continued guidance and prioritized reviews from the agency of an upcoming clinical trial, part of a process aimed at obtaining a pre-market approval.
January 11, 2023
Lung Cancer2 Social
Argus Research initiates coverage of BioAffinity Technologies at $9 per share
By LabPulse.com staff writers
BioAffinity's CyPath Lung lab-developed test uses flow cytometry and machine-learning algorithms to profile the approximately 20 million cells in an average sputum sample in less than 20 minutes.
December 19, 2022
Lung Cancer Social
University of Louisville developing experimental approach for lung cancer breath test
By Jared Berberabe
A research group is leveraging measurements of volatile organic compounds and machine learning to develop a test that detects lung cancer.
December 2, 2022
Lung Cancer Hotspot Social
Chest publication suggests potential for MagArray blood test to stratify lung cancer risk
By LabPulse.com staff writers
Its Knodule ID test is a multianalyte assay with algorithmic analysis comprising seven protein biomarkers and six clinical factors.
November 21, 2022
Cancer Lung Social
Biofidelity developing assay for single-molecule detection of multiple gene fusions
By LabPulse.com staff writers
The firm said its assay analyzes DNA and RNA concurrently from a single patient sample and can return results within two days.
October 18, 2022
Lung Cancer2 Social
Page 1 of 7
Next Page